Elena Tremoli is the Scientific Director of the Centro Cardiologico Monzino IRCCS and since 2017 has been the President of the Cardiology Network.
She obtained her degree in Pharmacological Sciences at the University of Pavia (Pavia, Italy) and continued her training at Centro Enrica Grossi Paoletti at the University of Milan (Milan, Italy). As part of her research program, she was visiting scientist at the Division of Hematology/Oncology of the Cornell Medical Center, New York Medical Hospital, in New York (NY, USA).
From 1990 to 2015, she was, first, Head of the Laboratory of Pharmacology of Thrombosis and Atherosclerosis at the Department of Pharmacological Sciences of the University of Milan (Milan, Italy), and then, from 2003 to 2009, Director of the Department.
In 2002, she was appointed Full Professor of Pharmacology at the University of Milan.
Since 2001, Prof. Tremoli has been Head of the Laboratory of Biochemistry and Molecular Biology of Atherothrombosis, at Centro Cardiologico Monzino IRCCS, where, on July 2011, she was nominated Scientific Director.
She serves as member of the scientific committee of several scientific societies and received, over the years, numerous scientific awards including the International Society of Atherosclerosis and the European Society for Non-Invasive and Preventive Cardiology awards.
She is co-author of more than 475 original articles and book chapters.
Her scientific interest is related to the study of human cardiac diseases to provide new insight into cellular and molecular mechanisms of diseases. Her clinical and pre-clinical research programs aim to identity novel diagnostic and prognostic markers, and risk factors of atherosclerosis, thrombosis, inflammation, cardiac injury and fibrosis.
Below, the main topic of her research:
- molecular and cellular biology of atherosclerosis and thrombosis with particular attention to the regulation of inflammatory and thrombotic system proteins in cells and tissues from humans and animal models;
- pharmacological control of thrombus formation to monitor the effectiveness of old and new therapies and the identification of coagulation and platelet activation markers in patients with cardiovascular diseases;
- studies of cerebral and myocardial ischemia in animal models of diseases, uding MRI imaging and other innovative imaging techniques;
- morphology and function of the vascular wall: imaging studies using ultrasounds in populations with risk factors for cardiovascular disease to identify markers of disease and monitor therapy effettiveness;
- studies of genetics, genomics, proteomics and metabolomics in selected patients with risk factors for cardiovascular disease.